These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 18774412)

  • 41. Abacavir use and risk of recurrent myocardial infarction.
    Sabin CA; Ryom L; d'Arminio Monforte A; Hatleberg CI; Pradier C; El-Sadr W; Kirk O; Weber R; Phillips AN; Mocroft A; Bonnet F; Law M; de Wit S; Reiss P; Lundgren JD;
    AIDS; 2018 Jan; 32(1):79-88. PubMed ID: 29028664
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CROI 2009: a few key presentations on antiretroviral therapy.
    Gallant JE
    AIDS Read; 2009 Apr; 19(4):129-30, C3. PubMed ID: 19388179
    [No Abstract]   [Full Text] [Related]  

  • 43. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
    Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS;
    AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Next HIV guidelines likely to include salvage therapy.
    AIDS Alert; 1999 Jul; 14(7):76-8. PubMed ID: 11366417
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 'Fine tuning' HIV therapy. Report on the 9th Conference on Retroviruses and Opportunistic Infections.
    Linde M
    Posit Living; 2002; 11(3):8-9, 16, 44. PubMed ID: 12035759
    [No Abstract]   [Full Text] [Related]  

  • 46. Comparing implications of cardiovascular risk of abacavir and integrase inhibitors: why scientific community is confused and timid?
    Guaraldi G; Milic J
    AIDS; 2023 May; 37(6):1005-1008. PubMed ID: 37017023
    [No Abstract]   [Full Text] [Related]  

  • 47. Chronic cough induced by abacavir apart from a context of hypersensitivity.
    Peyrière H; Mauboussin JM; Arnaud A; Rouanet I; Vincent D
    Allerg Immunol (Paris); 2002 Dec; 34(10):359-60. PubMed ID: 12575618
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Abacavir hypersensitivity reaction.
    AIDS Patient Care STDS; 2002 May; 16(5):242. PubMed ID: 12058699
    [No Abstract]   [Full Text] [Related]  

  • 49. Abacavir pharmacokinetics in hepatic dysfunction.
    Wyles DL; Gerber JG
    Clin Infect Dis; 2005 Mar; 40(6):909-10. PubMed ID: 15736035
    [No Abstract]   [Full Text] [Related]  

  • 50. Abacavir-induced reversible Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome.
    Ahmad M
    J Postgrad Med; 2006; 52(4):296-7. PubMed ID: 17102551
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Abacavir and increased risk of myocardial infarction.
    Edwards R; Bate A; Lindquist M
    Lancet; 2008 Sep; 372(9641):805. PubMed ID: 18774415
    [No Abstract]   [Full Text] [Related]  

  • 52. Abacavir plus lamivudine: a thymidine analogue-sparing NRTI backbone.
    Moyle GJ
    AIDS Read; 2003 Nov; 13(11):528, 533-5. PubMed ID: 14649622
    [No Abstract]   [Full Text] [Related]  

  • 53. Abacavir and lamivudine combination.
    Somboonwit C; Kurtyka D; Velez AP
    Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1599-606. PubMed ID: 19929448
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Glaxo opens broad expanded access program for abacavir (Ziagen).
    Baker R
    BETA; 1998 Apr; ():6. PubMed ID: 11365271
    [TBL] [Abstract][Full Text] [Related]  

  • 55. More on abacavir-induced neuropsychiatric reactions.
    Foster R; Taylor C; Everall IP
    AIDS; 2004 Dec; 18(18):2449. PubMed ID: 15622330
    [No Abstract]   [Full Text] [Related]  

  • 56. Incidence of abacavir hypersensitivity reactions in euroSIDA.
    Bannister WP; Friis-Møller N; Mocroft A; Viard JP; van Lunzen J; Kirk O; Gargalianos P; Bánhegyi D; Chiesi A; Lundgren JD;
    Antivir Ther; 2008; 13(5):687-96. PubMed ID: 18771052
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Differential adipose tissue gene expression profiles in abacavir treated patients that may contribute to the understanding of cardiovascular risk: a microarray study.
    Shahmanesh M; Phillips K; Boothby M; Tomlinson JW
    PLoS One; 2015; 10(1):e0117164. PubMed ID: 25617630
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Are we ready to RESPOND that the question of abacavir's role in cardiovascular disease events is settled?
    Fichtenbaum CJ; Mallon P
    AIDS; 2023 Mar; 37(3):541-543. PubMed ID: 36695364
    [No Abstract]   [Full Text] [Related]  

  • 59. Hypersensitivity reactions due to abacavir.
    Newsline People AIDS Coalit N Y; 1998 Feb; ():35-6. PubMed ID: 11367446
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Glaxo Wellcome's two new drugs.
    Res Initiat Treat Action; 1998 Dec; 4(7):14. PubMed ID: 11366081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.